Cite Score:
0.73
CITE SCORE SCOPUS

A comparing Study of Clarithromycin XL with Co-Amoxiclav for Treatment of Chronic Sinusitis; a Clinical Trial

AUTHORS

Maryam Amini 1 , * , Mohammadebrahim Yarmohammadi 2 , Pupak Izadi 2

1 Department of Infectious Diseases and Tropical Medicine, Faculty of Medicine, Shahed University, Tehran, IR Iran

2 Department of Otolaryngology (ENT), Faculty of Medicine, Shahed University, Tehran, IR Iran

How to Cite: Amini M, Yarmohammadi M, Izadi P. A comparing Study of Clarithromycin XL with Co-Amoxiclav for Treatment of Chronic Sinusitis; a Clinical Trial, Arch Clin Infect Dis. Online ahead of Print ; 4(4):197-201.

ARTICLE INFORMATION

Archives of Clinical Infectious Diseases: 4 (4); 197-201
Article Type: Research Article

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Chronic sinusitis is one of the most common medical problems affecting 30 million people in USA annually. In the present study, we compared the efficacy and safety of clarithromycin XL and co-amoxiclav on clinical and CT scan findings of patients suffering from chronic sinusitis.

Patients and Methods: In this clinical trial, a total of 59 subjects (37 males and 22 females, mean age 28 years) with clinical symptoms and CT scan findings of chronic sinusitis were assigned randomly in two groups and treated with clarithromycin XL or coamoxiclav.

Results: Clinical success rates were similar at the end of therapy period, however, subjects receiving clarithromycin XL showed better CT scan findings when compared with co-amoxiclav-treated subjects (53% versus 29%). Gastrointestinal discomfort was the most frequent treatmentrelated adverse effects in both groups (NS).

Conclusion: Results revealed that clarithromycin XL and co-amoxiclav have similar efficacy when considered for treatment of chronic sinusitis.

Keywords

Keywords: Chronic sinusitis, Clarithromycin, Co-amoxiclav

© 0, Archives of Clinical Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: